ReviewFuture medicinal chemistry2019
Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents.
Review in Future medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.Journal of women's health (2002) · 2023Trial
- Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).BJOG : an international journal of obstetrics and gynaecology · 2022Trial
- Anti-Fungal and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM).Drugs in R&D · 2026Article
- In silico pathway-based subtractive proteomics for identifying novel drug targets in Candida albicans with structure-guided drug repurposing of aspartate-semialdehyde dehydrogenase inhibitors.Journal of molecular modeling · 2026Article
- Combined Application of Probiotic and Phytobiotic Additives Improves Fermentation Quality and Amino Acid Preservation in Tropical Forage Silages.Animals : an open access journal from MDPI · 2026Article
- Sprayable dsRNA for integrated crop defense: mechanisms, delivery strategies, and translational challenges.Molecular biology reports · 2026Review
- Investigation of chitinase B1 inhibitors targeting the cell wall biosynthetic machinery in Aspergillus fumigatus through integrated molecular dynamics and QM/MM.Folia microbiologica · 2026Article
- [Screening of the anti-Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Antifungal Activity of Natural Thymol: Advances on Molecular Mechanisms and Therapeutic Potential.Biomolecules · 2026Review
- Antifungal Potential ofJournal of fungi (Basel, Switzerland) · 2026Article
- Mechanisms of action and biocontrol potential ofFrontiers in fungal biology · 2026Review
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Epidemiology of Fungal Bloodstream Infections and Antifungal Susceptibility in a Tertiary Care Hospital in Riyadh, Saudi Arabia: A RarePathogens (Basel, Switzerland) · 2025Article
- Antifungal Efficacy of Plasma-Activated Liquids againstACS omega · 2025Article
- Divergent Immunomodulatory Roles of Fungal DNA in Shaping Treg and Inflammatory Responses.Journal of fungi (Basel, Switzerland) · 2025Article
- Extended Antimicrobial Profile of Chromone-Butenafine Hybrids.Molecules (Basel, Switzerland) · 2025Article
- Multifaceted biomedical applications of biogenic titanium dioxide nanoparticles fabricated by marine actinobacterium Streptomyces vinaceusdrappus AMG31.Scientific reports · 2025Article
- Fungistatic activity and mechanism ofNarra J · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fungal infections are a worldwide problem associated with high morbidity and mortality. There are relatively few antifungal agents, and resistance has emerged within these pathogens for the newest antifungal drugs. As the fungal cell wall is critical for growth and development, it is one of the most important targets for drug development. In this review, the currently available cell wall inhibitors and suitable drug candidates for the treatment of fungal infections are explored. Future studies of the fungal cell wall and compounds that have detrimental effects on this important outer structural layer could aid in antifungal drug discovery and lead to the development of alternative cell wall inhibitors to fill gaps in clinical therapies for difficult-to-treat fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.